2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Epitech Group SpA: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients Micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) oral suspension, Standard Therapy - Covid19 | Phase 4 | Completed | Epitech Group SpA | 40 | 2020-10-23 | 2021-08-25 |
| Micronized and Ultramicronized Palmitoylethanolamide in Fibromyalgia Patients micronized and ultra-micronized Palmitoylethanolamide (mPEA and umPEA, 300mg + 600mg) microgranules, Placebo microgranules 1800mg, Standard Therapy - Fibromyalgia | Phase 4 | Completed | Epitech Group SpA | 21 | 2020-07-16 | 2023-09-07 |
COVID-19 (1) · Fibromyalgia (1)
Standard of Care (2) · Acetaminophen (1) · Drug Repositioning (1) · Suspensions (1)
Italy (2)